Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-DEP and PD-1 Antibody for EBV-Positive Lymphoma-associated HLH
NCT05775705Completed
- Sponsor
- Beijing Friendship Hospital
- Start
- Aug 2023
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial of Asparaginase, pegylated liposomal doxorubicin, etoposide and methylprednisolone in hemophagocytic lymphohistiocytosis (HLH), sponsored by Beijing Friendship Hospital. Primary endpoint: Response rate at 2 weeks. Started Aug 2023; status: completed.
02
Drugs
Asparaginasepegylated liposomal doxorubicinetoposidemethylprednisolone
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT05775705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775705.